Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

2014282 citationsJournal Articlebronze Open Access

Authors

Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.

Good health and well-being

Published in: Neuro-Oncology

Volume 17, Issue 1, pp. 116-121

Field-Weighted Citation Impact: 13.30